StockData
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. (ARMP) stock

ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$2.98−0.19 (-5.99%)

Close on Nov 19, 2026Market cap $110.80MP/E –Yield –

Armata Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Armata Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$25.79M. For fiscal 2025 it was -$26.31M. The highest annual figure on record is -$6.39M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.31M–
FY2024Dec 31, 2024-$39.43M–
FY2023Dec 31, 2023-$55.57M–
FY2022Dec 31, 2022-$34.69M–
FY2021Dec 31, 2021-$24.88M–
FY2020Dec 31, 2020-$19.09M–
FY2019Dec 31, 2019-$15.81M–
FY2018Dec 31, 2018-$11.50M–
FY2017Dec 31, 2017-$9.25M–
FY2016Dec 31, 2016-$10.89M–
FY2015Dec 31, 2015-$9.99M–
FY2014Dec 31, 2014-$13.77M–
FY2013Dec 31, 2013-$6.39M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.68M–
Q1 FY2026Mar 31, 2026-$5.85M–
Q4 FY2025Dec 31, 2025-$6.73M–
Q3 FY2025Sep 30, 2025-$4.54M–
Q2 FY2025Jun 30, 2025-$7.36M–
Q1 FY2025Mar 31, 2025-$7.68M–
Q4 FY2024Dec 31, 2024-$7.85M–
Q3 FY2024Sep 30, 2024-$9.20M–
Q2 FY2024Jun 30, 2024-$11.54M–
Q1 FY2024Mar 31, 2024-$10.83M–
Q4 FY2023Dec 31, 2023-$10.51M–
Q3 FY2023Sep 30, 2023-$13.20M–
Q2 FY2023Jun 30, 2023-$12.28M–
Q1 FY2023Mar 31, 2023-$19.58M–
Q4 FY2022Dec 31, 2022-$10.03M–
Q3 FY2022Sep 30, 2022-$11.63M–
Q2 FY2022Jun 30, 2022-$9.28M–
Q1 FY2022Mar 31, 2022-$3.75M–
Q4 FY2021Dec 31, 2021-$8.83M–
Q3 FY2021Sep 30, 2021-$5.55M–
Q2 FY2021Jun 30, 2021-$4.73M–
Q1 FY2021Mar 31, 2021-$5.77M–
Q4 FY2020Dec 31, 2020-$6.67M–
Q3 FY2020Sep 30, 2020-$3.96M–
Q2 FY2020Jun 30, 2020-$4.13M–
Q1 FY2020Mar 31, 2020-$4.34M–
Q4 FY2019Dec 31, 2019-$2.75M–
Q3 FY2019Sep 30, 2019-$4.50M–
Q2 FY2019Jun 30, 2019-$5.95M–
Q1 FY2019Mar 31, 2019-$2.60M–
Q4 FY2018Dec 31, 2018-$3.59M–
Q3 FY2018Sep 30, 2018-$2.18M–
Q4 FY2017Dec 31, 2017-$2.39M–
Q3 FY2017Sep 30, 2017-$626.00K–
Q2 FY2017Jun 30, 2017-$2.93M–
Q1 FY2017Mar 31, 2017-$3.30M–
Q4 FY2016Dec 31, 2016-$1.51M–
Q3 FY2016Sep 30, 2016-$3.16M–

More Armata Pharmaceuticals figures

See a number that looks wrong?